Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Latest Research Progress on Adenosine Antagonists
Latest Research Progress on Adenosine Antagonists
9 September 2023
Adenosine receptors play a crucial role in various physiological processes within the human body.
Read →
An Overview of ImmunoGen’s Drug Pipeline
R&D Pipeline
4 min read
An Overview of ImmunoGen’s Drug Pipeline
9 September 2023
ImmunoGen, Inc. is a biopharmaceutical company that was founded in 1981 and is based in Massachusetts, United States.
Read →
Roche's new generation of C5 complement monoclonal antibody, crovalimab, applies for market approval in the US
Latest Hotspot
3 min read
Roche's new generation of C5 complement monoclonal antibody, crovalimab, applies for market approval in the US
8 September 2023
Genentech, a member of the Roche, announced that the U.S. FDA has accepted the company's BLA for the novel complement C5 monoclonal antibody Crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read →
A Comprehensive Review of Flurandrenolide's R&D Innovations
Drug Insights
5 min read
A Comprehensive Review of Flurandrenolide's R&D Innovations
8 September 2023
This article summarized the latest R&D progress of Flurandrenolide, the Mechanism of Action for Flurandrenolide, and the drug target R&D trends for Flurandrenolide.
Read →
Alteogen's Tergase® Demonstrates Superior Immunogenicity Characteristics
Latest Hotspot
3 min read
Alteogen's Tergase® Demonstrates Superior Immunogenicity Characteristics
8 September 2023
Korean biotech firm Alteogen Inc. has publicized the findings of their most recent Tergase® clinical study, wherein no occurrence of ADA (inclusive of neutralizing antibodies) was found.
Read →
An Overview of Horizon Therapeutic’s Drug Pipeline | R&D Status
R&D Pipeline
4 min read
An Overview of Horizon Therapeutic’s Drug Pipeline | R&D Status
8 September 2023
Horizon Therapeutics Plc is a pharmaceutical organization based in Dublin, Ireland. It was founded in 2008 and has since been actively involved in the field of biomedicine.
Read →
EMA has applied for marketing authorization of ARCT-154 vaccine for the prevention of COVID-19 through Arcturus Therapeutics and CSL
Latest Hotspot
3 min read
EMA has applied for marketing authorization of ARCT-154 vaccine for the prevention of COVID-19 through Arcturus Therapeutics and CSL
8 September 2023
Arcturus Therapeutics Holdings have revealed today that EMA has officially confirmed the marketing authorization application for ARCT-154.
Read →
Review of ALK Inhibitors for Lung Cancer
Review of ALK Inhibitors for Lung Cancer
8 September 2023
ALK (Anaplastic Lymphoma Kinase) is a receptor tyrosine kinase that plays a crucial role in various physiological processes in the human body.
Read →
Pharmaceutical Insights: Succinylcholine Chloride's R&D Progress
Drug Insights
4 min read
Pharmaceutical Insights: Succinylcholine Chloride's R&D Progress
8 September 2023
This article summarized the latest R&D progress of Succinylcholine Chloride, the Mechanism of Action for Succinylcholine Chloride, and the drug target R&D trends for Succinylcholine Chloride.
Read →
EMA Approves Italfarmaco Group's Application for Givinostat Use in Duchenne Muscular Dystrophy Treatment
Latest Hotspot
4 min read
EMA Approves Italfarmaco Group's Application for Givinostat Use in Duchenne Muscular Dystrophy Treatment
8 September 2023
the Italfarmaco Group  has publicly declared that they have submitted a Marketing Authorization Application for Givinostat.
Read →
An Overview of Genmab’s Drug Pipeline | Therapeutic Areas
R&D Pipeline
4 min read
An Overview of Genmab’s Drug Pipeline | Therapeutic Areas
8 September 2023
Genmab A/S is a biopharmaceutical company based in Hovedstaden, Denmark.
Read →
Stoke Therapeutics provides data related to the ongoing clinical development of STK-001 for the treatment of Dravet syndrome
Latest Hotspot
4 min read
Stoke Therapeutics provides data related to the ongoing clinical development of STK-001 for the treatment of Dravet syndrome
8 September 2023
Stoke Therapeutics, Inc., reported today key points from presentations pertaining to the continued clinical research of STK-001.
Read →